| Literature DB >> 36153237 |
Rasha M Arabyat1, Mohammad B Nusair2, Sayer I Al-Azzam3, Haneen A Amawi4, Feras Darwish El-Hajji5.
Abstract
BACKGROUND: To date, there is no effective treatment for COVID-19. Vaccines are effective and safe strategies to control the pandemic.Entities:
Keywords: COVID-19 vaccine; Health Belief Model; Willingness to pay
Year: 2022 PMID: 36153237 PMCID: PMC9472461 DOI: 10.1016/j.sapharm.2022.09.003
Source DB: PubMed Journal: Res Social Adm Pharm ISSN: 1551-7411
Characteristics of survey respondents (N = 3116).
| Items | |
|---|---|
| Gender | |
| Female | 2300 (73.8%) |
| Male | 816 (26.2%) |
| 18–24 years | 1519 (48.8%) |
| 25–34 years | 570 (18.3%) |
| 35–44 years | 418 (13.4%) |
| 45–54 years | 376 (12.0%) |
| ≥55 years | 233 (7.5%) |
| Central | 1842 (59.1%) |
| North | 1104 (35.4%) |
| South | 170 (5.5%) |
| Less than 250 JOD | 347 (11.1%) |
| 250 JOD to 499 JOD | 1122 (36.1%) |
| 500 JOD to 999 JOD | 936 (30.0%) |
| 1000 JOD to 1499 JOD | 389 (12.48%) |
| More than 1500 JOD | 322 (10.3%) |
| Single | 1865 (59.9%) |
| Married | 1153 (37%) |
| Previously married | 98 (3.1%) |
| 1–3 | 496 (15.9%) |
| 4–6 | 1548 (49.7%) |
| 7–9 | 935 (30.0%) |
| ≥10 | 137 (4.4%) |
| 2165 (69.5%) | |
| 856 (27.5%) | |
| 931 (29.9%) | |
| 450 (14.4%) | |
| 886 (28.4%) | |
| Less than high school | 112 (3.6%) |
| High school/Diploma | 603 (19.4%) |
| Bachelor's degree | 2073 (66.5%) |
| Master/PhD degree | 328 (10.5%) |
| Currently employed | 1080 (34.7%) |
| Unemployed | 1844 (59.2%) |
| Retired | 192 (6.2%) |
| 1012 (32.5%) | |
| Negative PCR test | 2097 (67.4%) |
| Positive PCR test | 456 (14.7%) |
| Had symptoms but did not perform the PCR test | 560 (18.0%) |
| Negative PCR test | 732 (23.5%) |
| Positive PCR test | 2139 (68.7%) |
| Had symptoms but did not perform the PCR test | 245 (7.9%) |
| 740 (23.8%) | |
Fig. 1Maximum Willingness to Pay for the COVID-19 vaccine.
Summary of Health Belief Model responses as it applies to intentions to receive COVID-19 vaccine.
| Items | n (%) | alpha | Range | Mean (SD) |
|---|---|---|---|---|
| 0.78 | 1–5 | 3.31 (±0.69) | ||
| I will have side effects from the novel COVID-19 vaccine | 1–5 | 3.66 (±0.84) | ||
| I will get sick from the novel COVID-19 vaccine | 1–5 | 3.4 (±0.88) | ||
| I will die from the novel COVID-19 vaccine | 1–5 | 3.1 (±0.93) | ||
| The novel COVID-19 vaccine will be painful | 1–5 | 3.1 (±0.86) | ||
| 0.34 | ||||
| Even if I fall ill with another disease, I will not go to hospital because of risk of getting novel coronavirus/COVID-19 in the hospital | 1–5 | 3.6 (±1.1) | ||
| I am more likely to get the novel coronavirus/COVID-19 than other people | 1–5 | 2.35 (±1.1) | ||
| My family members are at risk of getting the novel COVID-19 | 1–5 | 3.0 (±0.99) | ||
| 0.70 | 1–5 | 3.34 (±0.72) | ||
| The novel COVID-19 vaccine will be expensive | 1–5 | 3.45 (±0.91) | ||
| I will not get the vaccine because it will run out | 1–5 | 3.25 (±0.90) | ||
| It will be difficult to get the novel COVID-19 vaccine | 1–5 | 3.33 (±0.92) | ||
| 0.87 | 3.52 (±0.82) | |||
| The novel COVID-19 vaccine will slow down the spread of the pandemic | 3.39 (±0.92) | |||
| The novel COVID-19 vaccine will help in improving the economy | 3.5 (±0.93) | |||
| The novel COVID-19 vaccine will reduce the burden on the healthcare system | 3.67 (±0.89) | |||
| I will get the COVID-19 vaccine if recommended to me by a healthcare provider | 1973 (63.3%) | |||
| I will get the COVID-19 vaccine if recommended to me by a family member | 291 (9.34%) | |||
| I will not take the COVID-19 vaccine no matter the recommendation | 853 (27.4%) | |||
| I think that the COVID-19 vaccine should be mandatory by the government | 1–5 | 2.84 (±1.3) |
Scales with an alpha coefficient of less than 0.5 were loaded separately in the regression model.
The scale mean was calculated for domains with an alpha coefficient >0.6.
Predictors of maximum WTP based on socio-demographic factors and constructs from the health belief model using ordinal logistic regression.
| Variables | Unadjusted Analysis | Adjusted Analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| UOR | SE | P-value | 95%CI | AOR | SE | P-value | 95%CI | |
| Gender | ||||||||
| Female | Ref | |||||||
| Male | 1.36 | 0.11 | <0.001 | 1.16–1.58 | 1.02 | 0.10 | 0.818 | 0.84–1.25 |
| 18–24 years | Ref | |||||||
| 25–34 years | 0.87 | 0.08 | 0.13 | 0.72–1.04 | 0.94 | 0.13 | 0.635 | 0.72–1.23 |
| 35–44 years | 0.67 | 0.07 | <0.001 | 0.54–0.83 | 0.82 | 0.15 | 0.280 | 0.58–1.17 |
| 45–54 years | 0.56 | 0.07 | <0.001 | 0.44–0.7 | 0.58 | 0.11 | 0.005 | 0.40–0.85 |
| ≥55 years | 0.93 | 0.12 | 0.585 | 0.72–1.21 | 0.58 | 0.14 | 0.024 | 0.36–0.93 |
| South | Ref | |||||||
| North | 1.6 | 0.26 | 0.004 | 1.16–2.21 | 1.74 | 0.32 | 0.003 | 1.21–2.50 |
| Central | 1.23 | 0.20 | 0.193 | 0.9–1.69 | 1.30 | 0.24 | 0.147 | 0.91–1.86 |
| Less than 250 JOD | Ref | |||||||
| 250 JOD to 499 JOD | 1.67 | 0.23 | <0.001 | 1.27–2.20 | 1.74 | 0.27 | <0.001 | 1.28–2.36 |
| 500 JOD to 999 JOD | 3.03 | 0.43 | <0.001 | 2.20–4.00 | 3.36 | 0.54 | <0.001 | 2.45–4.60 |
| 1000 JOD to 1499 JOD | 5.23 | 0.82 | <0.001 | 3.8–7.12 | 5.89 | 1.06 | <0.001 | 4.14–8.37 |
| More than 1500 JOD | 9.62 | 1.58 | <0.001 | 6.87–13.17 | 10.72 | 2.05 | <0.001 | 7.37–15.59 |
| Single | Ref | |||||||
| Married | 0.77 | 0.06 | <0.001 | 0.66–0.88 | 0.85 | 0.11 | 0.205 | 0.66–1.09 |
| Previously married | 0.47 | 0.11 | 0.001 | 0.30–0.74 | 0.75 | 0.22 | 0.325 | 0.43–1.33 |
| 1–3 | Ref | |||||||
| 4–6 | 0.88 | 0.09 | 0.208 | 0.73–1.07 | 0.69 | 0.08 | 0.002 | 0.55–0.87 |
| 7–9 | 0.76 | 0.08 | 0.011 | 0.62–0.94 | 0.59 | 0.08 | 0.000 | 0.45–0.76 |
| ≥10 | 0.75 | 0.14 | 0.136 | 0.52–1.10 | 0.58 | 0.13 | 0.013 | 0.38–0.89 |
| No | Ref | |||||||
| Yes | 1.13 | 0.09 | 0.108 | 0.97–1.32 | 1.27 | 0.12 | 0.008 | 1.07–1.52 |
| No | Ref | |||||||
| Yes | 2.02 | 0.15 | <0.001 | 1.75–2.34 | 1.49 | 0.13 | <0.001 | 1.25–1.76 |
| No | Ref | |||||||
| Yes | 1.15 | 0.11 | 0.151 | 0.95–1.40 | 1.40 | 0.17 | 0.007 | 1.1–1.78 |
| No | Ref | |||||||
| Yes | 1.16 | 0.09 | 0.046 | 1.00–1.35 | 0.96 | 0.09 | 0.639 | 0.80–1.15 |
| Less than high school | Ref | |||||||
| High school/Diploma | 1.18 | 0.24 | 0.42 | 0.79–1.76 | 0.85 | 0.19 | 0.474 | 0.54–1.33 |
| Bachelor's degree | 1.29 | 0.25 | 0.191 | 0.88–1.881 | 0.77 | 0.17 | 0.236 | 0.50–1.18 |
| Master/PhD degree | 2.36 | 0.51 | <0.001 | 1.55–3.59 | 1.08 | 0.27 | 0.784 | 0.66–1.76 |
| Unemployed | Ref | |||||||
| Currently employed | 1.36 | 0.10 | <0.001 | 1.18–1.57 | 1.25 | 0.13 | 0.033 | 1.02–1.53 |
| Retired | 1.14 | 0.17 | 0.378 | 0.85–1.51 | 1.46 | 0.31 | 0.078 | 0.96–2.23 |
| No | Ref | |||||||
| Yes | 1.75 | 0.13 | <0.001 | 1.52–2.02 | 1.18 | 0.10 | 0.035 | 1.02–1.40 |
| Negative PCR test | Ref | |||||||
| Positive PCR test | 0.88 | 0.09 | 0.213 | 0.72–1.07 | 0.81 | 0.09 | 0.071 | 0.65–1.02 |
| Had symptoms but not performed the PCR test | 0.75 | 0.07 | 0.002 | 0.62–0.90 | 0.81 | 0.09 | 0.05 | 0.66–1.01 |
| No | Ref | |||||||
| Yes | 1.15 | 0.09 | 0.084 | 0.98–1.35 | 1.22 | 0.11 | 0.029 | 1.02–1.46 |
| 0.45 | 0.03 | <0.001 | 0.40–0.50 | 0.81 | 0.06 | 0.004 | 0.70–0.94 | |
| 1.0 | 0.03 | 0.745 | 0.95–1.07 | |||||
| 1.1 | 0.04 | 0.005 | 1.03–1.12 | 1.03 | 0.04 | 0.397 | 0.96–1.11 | |
| 1.14 | 0.04 | <0.001 | 1.06–1.22 | 0.97 | 0.04 | 0.490 | 0.89–1.06 | |
| 1.18 | 0.06 | 0.001 | 1.07–1.30 | 0.95 | 0.06 | 0.420 | 0.85–1.07 | |
| 2.98 | 0.17 | <0.001 | 2.68–3.30 | 1.74 | 0.11 | <0.001 | 1.53–1.97 | |
| Ref | ||||||||
| 19.0 | 2.8 | <0.001 | 14.28–25.34 | 11.32 | 1.86 | <0.001 | 8.20–15.62 | |
| 14.63 | 2.6 | <0.001 | 10.32–20.77 | 9.76 | 1.92 | <0.001 | 6.62–14.37 | |
| No | Ref | |||||||
| Yes | 1.73 | 0.05 | <0.001 | 1.64–1.83 | 1.21 | 0.04 | <0.001 | 1.12–1.30 |
| 0.1923 | ||||||||
UOR: Unadjusted Odds Ratio.
SE: Standard Error.
CI: Confidence Interval.
AOR: Adjusted Odds Ratio.
*: Statistically significant variable.
Fig. 2Association between the reported monthly income and maximum willingness to payWTP: Willingness to Pay.
| JOD 5 | JOD 10 | JOD 15 | JOD 2 | JOD 25 | JOD 30 | JOD 40 | JOD 50 |
| JOD 75 | JOD 100 | JOD 150 | JOD 200 |